• John Hang Leung, LeungHenry W CHWCDepartment of Radiation Oncology, An-Nan Hospital, China Medical University, Tainan, Taiwan., Shyh-Yau Wang, Hei-Tung Yip Fion, and ChanAgnes L FALFDepartment of Pharmacy, An-Nan Hospital, China Medical University, Tainan, Taiwan..
• Department of Obstetrics and Gynecology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan.
• Medicine (Baltimore). 2024 May 24; 103 (21): e38183e38183.

BackgroundWe aimed to compare 7 newer immunotherapies and targeted therapies for platinum-resistant relapsed ovarian cancer.MethodsWe conducted a comprehensive search of PubMed, EMBASE, and Cochrane Library electronic databases for phase III trials involving platinum-resistant recurrent ovarian cancer (PRrOC) patients treated with immunotherapy or targeted therapy in combination with chemotherapy. The quality of the included trials was assessed using the GRADE method. The primary outcome of comparison was progression-free survival, and secondary outcomes included overall survival and safety.ResultsThis analysis included 7 randomized phase III controlled trials, encompassing 2485 PRrOC patients. Combining bevacizumab plus chemotherapy and lurbinectedin demonstrated statistically significant differences in progression-free survival compared to all other regimens of interest. However, no statistically significant differences were observed in the overall survival. Nivolumab and mirvetuximab exhibited fewer serious adverse events than the other regimens of interest.ConclusionsOur findings indicate that bevacizumab combined with chemotherapy and lurbinectedin monotherapy has significant efficacy in patients with PRrOC. For patients with PRrOC who have exhausted treatment options, nivolumab and mirvetuximab may be considered as alternatives because of their better safety profiles.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

35 keywords...

hide…